NEUREN’S VALUE PROPOSITION Leading pipeline in neurodevelopmental disorders Three key drivers transforming near term value Indication Compound Geography Preclinical Phase 1 Phase 2 Phase 3 Registration Commercial rights Rett Trofinetide US RoW NNZ-2591 World Fragile X Trofinetide World NNZ-2591 World PhelanMcDermid NNZ-2591 World Pitt Hopkins NNZ-2591 World Angelman NNZ-2591 World PraderWilli NNZ-2591 World pharmaceuticals Realise Neuren’s share of trofinetide value in the US through Acadia’s successful commercialization of Confirm efficacy of NNZ-2591 in Phase 2 trials for four valuable indications, with global rights retained by Neuren Positive top-line results for Phelan-McDermid syndrome • Top-line results for Pitt Hopkins and Angelman syndromes in Q2 and Q3 2024 Realise Neuren’s share of trofinetide ex-US value through expanded global partnership with Acadia 1 2 3 Key achievements in 2023 A$157 million profit after tax for 2023 Approval and successful launch of DAYBUE™ (trofinetide) in the US as the first approved treatment for Rett syndrome, with net sales for 2023 since launch in April of US$177 million Expansion of DAYBUE™ (trofinetide) partnership with Acadia to include ex-North America, delivering A$146 million up-front plus attractive future royalties and milestone payments Highly encouraging positive results in Phase 2 trial of NNZ-2591 for Phelan-McDermid syndrome Completion of enrolment in Phase 2 trials of NNZ-2591 for Pitt Hopkins and Angelman syndromes Neuren Pharmaceuticals Limited Annual Report 2023 1
RkJQdWJsaXNoZXIy MjE2NDg3